Surgery significantly improves survival in patients with chordoma

Spine

Volumn 35, Issue 1, 2010, Pages 117-123

  Jawad, Muhammad Umar ^a   Scully, Sean P ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Chordoma; Prognostic factors; SEER database; Surgical resection; Survival outcomes

Indexed keywords

ADULT; AGE DISTRIBUTION; ARTICLE; CANCER DIAGNOSIS; CANCER LOCALIZATION; CANCER RECURRENCE; CANCER REGISTRY; CANCER SIZE; CANCER STAGING; CANCER SURGERY; CHILD; CHORDOMA; CONTROLLED STUDY; ETHNICITY; FEMALE; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; MORBIDITY; PRIORITY JOURNAL; PROGNOSIS; RACE DIFFERENCE; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AFRICAN AMERICANS; AGE FACTORS; AGED; AGED, 80 AND OVER; BONE NEOPLASMS; CHI-SQUARE DISTRIBUTION; CHILD; CHILD, PRESCHOOL; CHORDOMA; COMBINED MODALITY THERAPY; DATABASES, FACTUAL; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HISPANIC AMERICANS; HUMANS; INCIDENCE; INFANT; INFANT, NEWBORN; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE; TREATMENT OUTCOME; UNITED STATES;

EID: 76149129041     PISSN: 03622436     EISSN: 15281159     Source Type: Journal    
DOI: 10.1097/BRS.0b013e3181b44387     Document Type: Article

References (56)

1. Ho KL. Ecchordosis physaliphora and chordoma: a comparative ultrastructural study. Clin Neuropathol 1985;4:77-86.
2. Salisbury JR. The pathology of the human notochord. J Pathol 1993;171: 253-255
3. Chugh R, Tawbi H, Lucas DR, et al. Chordoma: the nonsarcoma primary bone tumor. Oncologist 2007;12:1344-1350
4. Deshpande V, Nielsen GP, Rosenthal DI, et al. Intraosseous benign notochord cell tumors (BNCT): further evidence supporting a relationship to chordoma. Am J Surg Pathol 2007;31:1573-1577
5. Casali PG, Messina A, Stacchiotti S, et al. Imatinib mesylate in chordoma. Cancer 2004;101:2086-2097
6. Sciubba DM, Chi JH, Rhines LD, et al. Chordoma of the spinal column. Neurosurg Clin N Am 2008;19:5-15.
7. Catton C, O'Sullivan B, Bell R, et al. Chordoma: long-term follow-up after radical photon irradiation. Radiother Oncol 1996;41:67-72.
8. Chambers PW, Schwinn CP. Chordoma: a clinicopathologic study of metastasis. Am J Clin Pathol 1979;72:765-776
9. Higinbotham NL, Phillips RF, Farr HW, et al. Chordoma. Thirty-five-year study at Memorial Hospital. Cancer 1967;20:1841-1850
10. Baratti D, Gronchi A, Pennacchioli E, et al. Chordoma: natural history and results in 28 patients treated at a single institution. Ann Surg Oncol 2003; 10:291-296 (Pubitemid 40486963)
11. Bergh P, Kindblom LG, Gunterberg B, et al. Prognostic factors in chordoma of the sacrum and mobile spine: a study of 39 patients. Cancer 2000;88: 2122-2134
12. Fuchs B, Dickey ID, Yaszemski MJ, et al. Operative management of sacral chordoma. J Bone Joint Surg Am 2005;87:2211-2216
13. Hulen CA, Temple HT, Fox WP, et al. Oncologic and functional outcome following sacrectomy for sacral chordoma. J Bone Joint Surg Am 2006;88: 1532-1539
14. Osaka S, Kodoh O, Sugita H, et al. Clinical significance of a wide excision policy for sacrococcygeal chordoma. J Cancer Res Clin Oncol 2006;132:213-218
15. Yonemoto T, Tatezaki S, Takenouchi T, et al. The surgical management of sacrococcygeal chordoma. Cancer 1999;85:878-883
16. Hanna SA, Aston WJ, Briggs TW, et al. Sacral chordoma: can local recurrence after sacrectomy be predicted? Clin Orthop Relat Res 2008;466:2217-2223
17. Boriani S, Bandiera S, Biagini R, et al. Chordoma of the mobile spine: fifty years of experience. Spine 2006;31:493-503.
18. Dorfman HD, Czerniak B. Bone cancers. Cancer 1995;75:203-210
19. Dreghorn CR, Newman RJ, Hardy GJ, et al. Primary tumors of the axial skeleton: experience of the Leeds regional bone tumor registry. Spine 1990; 15:137-140
20. Eriksson B, Gunterberg B, Kindblom LG. Chordoma. A clinicopathologic and prognostic study of a Swedish national series. Acta Orthop Scand 1981; 52:49-58.
21. O'Neill P, Bell BA, Miller JD, et al. Fifty years of experience with chordomas in southeast Scotland. Neurosurgery 1985;16:166-170
22. Paavolainen P, Teppo L. Chordoma in Finland. Acta Orthop Scand 1976; 47:46-51.
23. Price CH, Jeffree GM. Incidence of bone sarcoma in SW England, 1946-1974, in relation to age, sex, tumour site and histology. Br J Cancer 1977;36:511-522
24. McMaster ML, Goldstein AM, Bromley CM, et al. Chordoma: incidence and survival patterns in the United States, 1973-1995. Cancer Causes Control 2001;12:1-11.
25. World Health Organization. International Agency for Research on Cancer. International Classification of Diseases for Oncology. 3rd ed. Geneva, Switzerland: World Health Organization; 2000.
26. Bach PB, Guadagnoli E, Schrag D, et al. Patient demographic and socioeconomic characteristics in the SEER-Medicare database applications and limitations. Med Care 2002;40:IV-19-25.
27. Cooper GS, Virnig B, Klabunde CN, et al. Use of SEER-Medicare data for measuring cancer surgery. Med Care 2002;40:IV-43-48
28. Earle CC, Nattinger AB, Potosky AL, et al. Identifying cancer relapse using SEER-Medicare data. Med Care 2002;40:IV-75-81.
29. Gloeckler Ries LA, Reichman ME, Lewis DR, et al. Cancer survival and incidence from the Surveillance, Epidemiology, and End Results (SEER) program. Oncologist 2003;8:541-552
30. Hayat MJ, Howlader N, Reichman ME, et al. Cancer statistics, trends, and multiple primary cancer analyses from the Surveillance, Epidemiology, and End Results (SEER) Program. Oncologist 2007;12:20-37.
31. Merrill RM, Dearden KA. How representative are the surveillance, epidemiology, and end results (SEER) program cancer data of the United States? Cancer Causes Control 2004;15:1027-1034
32. Petrelli NJ. SEER data: it can be thought provoking, but where do we go from here? Ann Surg Oncol 2007;14:2173-2174
33. Wingo PA, Jamison PM, Hiatt RA, et al. Building the infrastructure for nationwide cancer surveillance and control-a comparison between the National Program of Cancer Registries (NPCR) and the Surveillance, Epidemiology, and End Results (SEER) Program (United States). Cancer Causes Control 2003;14:175-193
34. National Cancer Institute. Surveillance, Epidemiology and End Results (SEER) Program. Bethesda, MD: National Cancer Institute; 2008.
35. AJCC. AJCC Cancer Staging Manual. 6th ed. New York, NY: Springer; 2003.
36. NCI. Available at: http://seer.cancer.gov/csr/1975-2005/index.html. Accessed 2009.
37. Shwartz M, Pliskin JS, Grondahl HG, et al. Use of the Kaplan-Meier estimate to reduce biases in estimating the rate of caries progression. Community Dent Oral Epidemiol 1984;12:103-108
38. Tzortzidis F, Elahi F, Wright D, et al. Patient outcome at long-term follow-up after aggressive microsurgical resection of cranial base chordomas. Neurosurgery 2006;59:230-7; discussion: 7.
39. Jawad MU, Cheung MC, Min E, et al. Ewing's sarcoma demonstrates racial disparities in incidence and gender related differences in outcome: an analysis of 1631 cases from SEER Database. Cancer 2009;115:3526-3536
40. Cope JU. A viral etiology for Ewing's sarcoma. Med Hypotheses 2000;55: 369-372
41. Kebudi R, Bilgic B, Gorgun O, et al. Is the Epstein Barr virus implicated in Ewing sarcoma? Med Pediatr Oncol 2003;40:256-257
42. Valery PC, McWhirter W, Sleigh A, et al. A national case-control study of Ewing's sarcoma family of tumours in Australia. Int J Cancer 2003;105:825-830
43. Riva P, Crosti F, Orzan F, et al. Mapping of candidate region for chordoma development to 1p36.13 by LOH analysis. Int J Cancer 2003;107:493-497
44. Bridge JA, Pickering D, Neff JR. Cytogenetic and molecular cytogenetic analysis of sacral chordoma. Cancer Genet Cytogenet 1994;75:23-25
45. Klingler L, Shooks J, Fiedler PN, et al. Microsatellite instability in sacral chordoma. J Surg Oncol 2000;73:100-103
46. Eisenberg MB, Woloschak M, Sen C, et al. Loss of heterozygosity in the retinoblastoma tumor suppressor gene in skull base chordomas and chondrosarcomas. Surg Neurol 1997;47:156-60; discussion: 60-61
47. Dalpra L, Malgara R, Miozzo M, et al. First cytogenetic study of a recurrent familial chordoma of the clivus. Int J Cancer 1999;81:24-30.
48. Kaneko Y, Sato Y, Iwaki T, et al. Chordoma in early childhood: a clinicopathological study. Neurosurgery 1991;29:442-446
49. Sibley RK, Day DL, Dehner LP, et al. Metastasizing chordoma in early childhood: a pathological and immunohistochemical study with review of the literature. Pediatr Pathol 1987;7:287-301.
50. Coffin CM, Swanson PE, Wick MR, et al. Chordoma in childhood and adolescence. A clinicopathologic analysis of 12 cases. Arch Pathol Lab Med 1993;117:927-933
51. Nolte K. Malignant intracranial chordoma and sarcoma of the clivus in infancy. Pediatr Radiol 1979;8:1-6.
52. Klingler L, Trammell R, Allan DG, et al. Clonality studies in sacral chordoma. Cancer Genet Cytogenet 2006;171:68-71.
53. Berven S, Zurakowski D, Mankin HJ, et al. Clinical outcome in chordoma: utility of flow cytometry in DNA determination. Spine 2002;27:374-379
54. Gunterberg B, Kewenter J, Petersen I, et al. Anorectal function after major resections of the sacrum with bilateral or unilateral sacrifice of sacral nerves. Br J Surg 1976;63:546-554
55. Gunterberg B, Norlen L, Stener B, et al. Neurourologic evaluation after resection of the sacrum. Invest Urol 1975;13:183-188
56. Smolders D, Wang X, Drevelengas A, et al. Value of MRI in the diagnosis of non-clival, non-sacral chordoma. Skeletal Radiol 2003;32:343-350